Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
BioCryst makes and sells medicines for rare diseases, including a daily pill for a painful swelling condition and an antiviral flu drug.
BioCryst Pharmaceuticals is a small drugmaker that focuses on rare diseases — illnesses that few people have, which means few companies bother to treat them. Its lead product is Orladeyo, a once-a-day pill for hereditary angioedema, a genetic condition that causes sudden, painful swelling in places like the hands, face, belly, and throat. Before Orladeyo, patients mostly managed the disease with injections or infusions, so a simple capsule was a genuine change in daily life.
The business model is straightforward: the company develops a drug, gets it approved by regulators, and then sells it, mostly in the United States, while collecting government-granted exclusivity that keeps copycat versions off the market for a set number of years. Orladeyo is the profit engine, and BioCryst is racing to get it approved and reimbursed in more countries, since each new market adds patients without adding much cost. The company also sells RAPIVAB, an intravenous flu treatment used mainly in hospitals, though it is a much smaller piece of the story. The obvious risk is concentration: one drug pays most of the bills. Orladeyo competes against established injectable therapies from larger rivals, and a newer wave of oral competitors is coming, so BioCryst must keep patients on its pill and keep expanding abroad. The company historically burned cash for years before Orladeyo turned it profitable on an adjusted basis, and it still carries debt from its earlier lean times.
What makes BioCryst interesting is the bet underneath it: that patients would rather swallow a pill every day than give themselves shots, and that a small company can carve out a real business by going after diseases the giants ignore.
Saved answer · last researched 15 Nov 2026